Form 8-K Humacyte, Inc. For: Mar 19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- BuzzFeed cuts 35% of workforce in restructuring move
Humacyte suspends $60 million stock offering program
March 19, 2026 8:28 AM EDTHumacyte Inc. (NASDAQ: HUMA) terminated its at-the-market equity offering program on March 19, 2026, according to a company statement.
The biotechnology company delivered written notice to TD Securities (USA) LLC, which served as the sales agent, suspending the prospectus dated December 16, 2025. The prospectus... More
